Results 151 to 160 of about 11,748,761 (306)

Maps, Mirrors, and Participants: Design Lenses for Sociomateriality in\n Engineering Organizations [PDF]

, 2020
Edward Burnell, Priya P. Pillai, Maria C. Yang   +2 more
openalex   +1 more source

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

Molecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source

Publisher Correction: Editors' Choice 2025. [PDF]

Commun Eng
Liu P, Coatsworth P, Neto P, Tian L, de Carvalho Castro E Silva C, Huang C, Daw R, Elias S, Behnood A, Schofield JS, Rizzo A, Perlman O, Raney J, Chen WG, Fujii M, Tingley DD, Wang W, Mastrangeli M.   +17 more
europepmc   +1 more source

1st International Conference on Advances in Engineering and Technology (ICAET-2018).

, 2018

openalex   +1 more source

GraftNet: An Engineering Implementation of CNN for Fine-grained Multi-label Task [PDF]

, 2020
Chunhua Jia, Lei Zhang, Hui Huang, Weiwei Cai, Hao Hu, Rohan Adivarekar   +5 more
openalex   +1 more source

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

Molecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon, Dong Young Kim, Yuna Kim, Uk‐Il Kim, Jae‐Sung Kim   +4 more
wiley   +1 more source

Table of Contents

Engineering Transactions, 2013
Engineering Transactions Engineering Transactions
doaj   +2 more sources

Cotargeting TREM2 and IL2 pathways triggers multipronged anticancer immunity

Molecular Oncology, EarlyView.
Von Locquenghien et al. report that MiTE‐144, a triggering receptor expressed on myeloid cells 2 (TREM2) blocking antibody fused to interleukin‐2 (IL2) variant with tumour microenvironment restricted activation, demonstrates superior anticancer efficiency in a preclinical setting.
Isaure Vanmeerbeek, Jenny Sprooten, Abhishek D. Garg   +2 more
wiley   +1 more source

Retraction Note: Enhancing residential energy access with optimized stand-alone hybrid solar-diesel-battery systems in Buea, Cameroon. [PDF]

Sci Rep
Amoussou I, Paddy EY, Agajie TF, Ibrahim FS, Agajie EF, Nsanyuy WB, Bajaj M, Mohammadi SAD.   +7 more
europepmc   +1 more source

The 2018 5th International Conference on Advanced Materials, Mechanics and Structural Engineering [PDF]

, 2019

openalex   +1 more source